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Resumo 
As aquaporinas (AQPs) são proteínas transmembranares responsáveis pelo transporte de água e 
de outros solutos, como o glicerol, através das membranas plasmáticas.  
Estes transportadores entraram recentemente na lista de possíveis alvos terapêuticos na área da 
oncobiologia uma vez que a sua sobre-expressão está associada a diferentes tipos de cancro. Em 
particular a aquaporina-3 (AQP3), uma aquagliceroporina abundantemente expressa ao nível da 
epiderme, é agora tida como “chave” na tumorigénese e quimioresistência em casos de cancro 
de pele. Deste modo, as AQPs estão a ganhar relevância enquanto alvos biológicos na terapia do 
cancro e os seus modeladores a reunir interesse por parte da indústria farmacêutica. 
Recentemente, o nosso grupo descreveu diferentes compostos baseados em iões metálicos como 
inibidores potentes e selectivos da AQP3 humana. Em particular, o composto derivado de 
cobre(II) da fenantrolina – Cuphen – demonstrou ter efeito inibitório selectivo sobre a 
permeabilidade ao glicerol quando testado em eritrócitos humanos, mostrando-se assim 
promissor para administração in vivo. 
Por conseguinte, este trabalho teve como principal objectivo o desenvolvimento de um sistema 
de veiculação adequado, baseado em estruturas lipídicas artificiais, nomeadamente lipossomas, 
de modo a poder permitir uma estabilização de inibidores da AQP3, alterando o seu perfil de 
biodistribuição in vivo, proporcionando um direccionamento preferencial para as áreas de 
interesse terapêutico aquando da sua administração. 
Assim, e recorrendo à linha celular tumoral A431, derivada de carcinoma epidermoide humano, 
e que apresenta sobre-expressão endógena de AQP3, foi avaliado o potencial citotóxico de 
diferentes compostos metálicos inibidores da AQP3. Após identificação do composto mais 
citotóxico, o Cuphen (([Cu(phen)Cl2]Cl (phen = 1,10-fenantrolina)), já descrito como inibidor 
selectivo da AQP3 em eritrócitos humanos, foi seleccionado para incorporação em lipossomas 
de escala nanométrica (inferior a 0.2 µm). Usando diferentes composições lipídicas foram 
obtidas eficiências de incorporação de cerca de 50%. 
O efeito citotóxico do Cuphen, nas formas livre e lipossomal, foi avaliado na linha celular A431 
e numa linha de cancro de cólon de murganho (C26). Para a forma livre, obtiveram-se valores 
de IC50 de 3.0 ± 0.4 µM e 1.8 ± 0.1 µM para as linhas A431 e C26, respectivamente, após 72h 
de incubação. A incorporação do Cuphen em lipossomas permitiu a preservação do seu efeito 
citotóxico (IC50 ≤ 10 µM após 72h de incubação).  
É ainda de referir que os lipossomas vazios não apresentaram qualquer efeito a nível da 
viabilidade das células testadas. 
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Com base nestes resultados, o estudo de formulações lipossomais para encapsular este inibidor 
deve ser aprofundado e o estabelecimento de um modelo animal de melanoma humano deve ser 
considerado, por forma a avaliar o efeito terapêutico deste composto metálico.  
 
 
 
Palavras-chave: Aquaporina-3, cancro, Cuphen, lipossomas. 
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Abstract 
Aquaporins (AQPs) are a family of small transmembrane proteins that facilitate the transport of 
water and other solutes, such as glycerol, across the cell plasma membrane. AQPs are now part 
of the expanding list of effectors in cancer biology after establishment of positive correlations 
between the histological tumor grade and their aberrant expression in different tumor types. In 
particular, the AQP3 aquaglyceroporin, which is abundantly expressed in skin keratinocytes, is 
now seen as a key player in skin tumorigenesis and chemoresistance. Therefore, AQPs are 
gaining relevance as drug targets for cancer therapy and AQPs' modulators are gathering interest 
from the pharmaceutical industry.  
Our group recently reported different metallodrugs as potent and selective human AQP3 
inhibitors for further exploitation on in vivo studies. Pursuing this idea, this work had as major 
aim the development of appropriate drug carrier systems based on artificial closed structures 
formed by lipid bilayers – liposomes – that may stabilize AQP3 inhibitors and improve in vivo 
delivery.  
With this aim, a cytotoxic screening using different AQP3 inhibitors against a human 
epidermoid carcinoma cell line (A431), presenting endogenous overexpression of AQP3, was 
performed. Cuphen ([Cu(phen)Cl2]Cl (phen = 1,10-phenantroline)), previously shown to 
selectively inhibit AQP3 glycerol transport in human red blood cells, was selected as the most 
promising inhibitor and incorporated in liposomes in a nanometric scale (below 0.2 µm). Using 
different lipid compositions, incorporation efficiencies of approximately 50% were achieved. 
The in vitro cytotoxic effect of Cuphen, in both free and liposomal forms, was assessed in the 
A431 and the C26 murine colon cancer cell lines. In the free form, the IC50 obtained was 3.0 ± 
0.4 µM and 1.8 ± 0.1 µM for the A431 and for C26, respectively, after 72h of incubation. The 
incorporation of Cuphen in liposomes was able to preserve the cytotoxic effect of this AQP3 
inhibitor (IC50 ≤ 10 µM after 72h of incubation). Moreover, unloaded liposomes did not exert 
any effect on the viability of these cancer cells.  
In view of these in vitro results, more liposomal formulations should be tested and the 
establishment of a murine melanoma model to evaluate the therapeutic effect of Cuphen 
formulations should be considered. 
 
 
 
Keywords: Aquaglyceroporin-3, cancer, Cuphen, liposomes. 
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1.1. Aquaporins 
Aquaporins (AQPs) are a family of small (≈30 kDa) ubiquitous transmembrane proteins that 
facilitate the bidirectional transport of water and small uncharged molecules such as glycerol or 
urea and, in particular cases, ammonia, carbon dioxide and hydrogen peroxide, across the lipid 
bilayer. (Agre, 1993; Wu, 2007) 
The first water channel (AQP1) was reported in 1992 by Preston and co-workers, after 
purification and subsequent characterization of a protein isolated from red blood cells (RBCs) in 
Xenopus oocytes (Preston, 1992) and its reconstitution into liposomes. (Zeidel, 1992) Since 
then, several AQPs were identified from yeast, plants and animals. (Kruse, 2006) 
 
Table 1.1. Permeability and occurrence of human aquaporins. Modified from (Castle, 2005). 
AQP Permeants Major tissue distribution 
AQP0 ↓ Water Lens (eye) 
AQP1 
↑ Water 
CO2; NO (Carbrey, 2009) 
Erythrocytes, lung, kidney, brain, eye and 
vascular endothelium 
AQP2 ↑ Water Kidney 
AQP3 
↑ Water 
↑ glycerol;  
urea 
H2O2 (Miller, 2010) 
Skin, kidney, lung, eye and GI tract 
AQP4 ↑ Water Kidney, brain, lung, GI tract and muscle 
AQP5 ↑ Water 
Salivary, lacrimal and sweat glands, lung and 
eye 
AQP6 
↓ Water 
Anions (NO3> Cl
-
) (Carbrey, 2009) Kidney 
AQP7 
↑ Water 
↑ glycerol; urea (Wspalz, 2009) 
Arsenite (Carbrey, 2009) 
Adipose tissue, kidney and testis 
AQP8 
↑ Water 
urea; ammonia (Wspalz, 2009)  
H2O2 (Wu, 2007) 
Kidney, liver, pancreas, GI tract and testis 
AQP9 
↓ Water 
↑ glycerol; urea (Wspalz, 2009) 
Arsenite (Carbrey, 2009) 
Liver, leukocytes, brain and testis 
AQP10 
↓ Water 
↑ glycerol; urea (Wspalz, 2009) 
GI tract 
AQP11 NK Brain, liver, kidney 
AQP12 NK Pancreas (Ishibashi, 2009) 
NK – not known. 
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In humans, 13 different AQP isoforms are known (AQP0-AQP12) and they are classified into 
two different subgroups according to their ability to strictly transport water or also other small 
molecules such as glycerol: the orthodox aquaporins (AQP0, AQP1, AQP2, AQP4, AQP5, 
AQP6, AQP8) and the aquaglyceroporins (AQP3, AQP7, AQP9, AQP10). Additionally, AQP11 
and AQP12 were found in intracellular membranes but their function is yet not defined. (Magni, 
2006; Ishibashi, 2009)  
Mammalian AQPs are organ, tissue and localization specific, being differentially expressed in 
epithelial tissues involved in fluid transport (e.g. epithelia from kidney and intestine) but also in 
other non-fluid transporting tissues such as skin, fat and brain. Table 1.1 shows the tissue 
distribution of AQPs in mammals. 
 
 
1.1.1. Structure of aquaporins  
AQPs are homotetrameric proteins (featuring four independent pores) with approximately 270 
amino acids per monomer, each monomer behaving as a water channel. All AQPs share a 
similar structure (Figure 1.1) where, in general, each monomer comprises six membrane-
spanning helical domains (H1-H6), organized in two distinct halves (H2, H1, H3 and H5, H4, 
H6) that interact to form a pore. These six highly hydrophobic transmembrane spanning helices 
are connected by five loops: three extracellular - loops A, C and E, and two intracellular – loops 
B and D. Both amino- and carboxyl- terminal ends are cytoplasmatic. Loops B and E present a 
consensus motif highly conserved, asparagine–proline–alanine (NPA; single letter code for 
amino acid) considered the channel signature and crucial for selectivity, namely the water/solute 
specificity. 
 
Figure 1.1. Structural organization of an AQP1 monomer. In the membrane, the six α helices form a 
right-handed twisted arrangement. However and to simplify, the helices 3, 1 and 2 are drawn separated 
from helices 5, 4 and 6. Adapted from (Zeuthen, 2001). 
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Loops B and E, which are shaped into small α helices as shown in Figure 1.2, fold back into the 
membrane and interact with the entire protein structure through hydrogen-bonds and several ion 
pairs. They also interact with each other by Van der Waal interactions between the proline 
residues of the NPA motifs. Thus, they are essential for the physiological role of AQPs in 
different ways: NPA motifs have both functional and positional relevance. 
 
  
Figure 1.2. Representation of hAQP1 monomers (side view). Generated on Chimera. PDB ID: 1H6I. 
A| All the helices and loops are shown. B| Representation of loops B and E with the Proline residues of 
the NPA motif shown in dark blue. 
 
Viewed from top of the extracellular surface, the six α helices form a right-handed, twisted 
arrangement. AQPs structure is achieved and maintained from the large crossing angles between 
helices, local fits between helices - ridges and grooves, and from interactions of highly 
conserved residues of Glycine at the crossing sites. (Zeuthen, 2001; Kruse, 2006) 
 
 
1.1.2. Pore Structure of AQPs 
Essential differences are found between aquaporins and aquaglyceroporins. In general, the pores 
of AQPs are roughly 25 Å long and exhibit two sites which interact strongly with water 
molecules: a constriction site and the NPA motif. 
The first site of “selectivity” is located close to the relatively wide extracellular top of the pore: 
the diameter of this opening in orthodox aquaporins is approximately 2.8 Å, i.e. identical to that 
of a water molecule, while in aquaglyceroporins this opening is about 3.4 Å, matching the 
diameter of carbon hydroxyl groups of polyols such as glycerol. This constriction site is known 
as aromatic residue/arginine (ar/R) and is generally more hydrophobic in aquaglyceroporins. 
A| B| 
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The second interaction site is the NPA motif, the key for water/solute specificity. This region is 
larger than the ar/R, and it is located in the center of the pore (Figure 1.3). The small α helices at 
the end of loops B and E are capped with two polar uncharged amino-acids, two asparagines. 
These residues act like hydrogen donors to the oxygen atoms of the permeants. In addition, the 
water molecules that enter the pore are reoriented by the dipoles of the half helices (loops B and 
E), avoiding the formation of hydrogen bonds between adjacent water molecules. This dipole is 
also responsible for the exclusion of protons from the central region of the channel, through the 
free energy barrier that is generated.  
 
 
Figure 1.3. Detailed view of a bAQP1 (bos taurus) pore region (red mesh). Half helices dipoles and 
the hydrophilic and hydrophobic residues lining the pore are depicted in red and yellow, respectively. 
(Soveral G, 2011) 
 
The NPA motif also confers size selectivity. In orthodox AQPs, the central region of the pore 
presents a leucine residue opposite to a phenylalanine (bulky side chain), while in 
aquaglyceroporins two leucine residues oppose to two asparagines. Thus, the pores of 
aquaglyceroporins are suitable for solutes larger than water. 
The remaining residues, from the NPA to the intracellular top of the pore, exhibit hydrophobic 
side chains, with the carbonyls of the backbone exposed to the pore surface. The oxygen atoms, 
lined-up along one side of the pore, serve as hydrogen bond acceptors leading to an efficient 
transport of small hydrogen bond donors, such as water, urea or glycerol. (Wspalz, 2009) 
Regarding the AQP gating, many factors are now known and well described, such as pH, 
osmotic stress, and even membrane tension or (de)activation through phosphorylation. (Soveral 
G, 2011) 
 
 
1. Introduction 
 
7 
 
1.2. AQP selectivity 
1.2.1. Orthodox aquaporins 
AQP1 is mainly found in erythrocytes and renal proximal tubules. (King, 2004) AQP1 water 
channels allow water to move freely and bidirectionally across the cell membrane, but exclude 
all ions including hydroxide, hydronium ions and protons, the later being essential to preserve 
the electrochemical potential across the membrane. It was recently described that AQP1 is also 
permeable to gases, such as carbon dioxide (CO2) and nitric oxide (NO). However, the 
mechanism and the physiological relevance of this permeability (namely to CO2) is still under 
debate and, thus far, this was the only AQP reported to be permeable to this gas. (Carbrey, 
2009) 
AQP0, AQP2, AQP4 and AQP5 are reported as strict water channels. (Takata, 2004) 
AQP6 has been considered a special case, since it showed a low affinity for water (being only 
slightly permeable) but in contrast, is permeable to anions, namely nitrate and chloride. 
(Carbrey, 2009)  
AQP8 is another particular case. Although with high affinity for water this channel also 
permeates hydrogen peroxide (Wu, 2007; Bertolotti, 2013) and was reported as a transporter for 
uncommon solutes such as ammonia derivates. (Liu, 2006) 
 
1.2.2. Aquaglyceroporins 
Aquaglyceroporins transport glycerol or other uncharged solutes in addition to water.  
Compared with other mammalian orthodox aquaporins, namely with AQP1, AQP3 is 
moderately permeable to water, but highly permeable to glycerol and, possibly, to urea. 
Although unexpected, it was recently proposed to also act as a hydrogen peroxide channel, 
alongside with AQP8. (Miller, 2010; Bertolotti, 2013) 
When expressed in Xenopus oocytes, the isoforms AQP7 and AQP10 were shown to transport 
water, glycerol and urea (Wspalz, 2009), while AQP9 was reported to transport all of these 
solutes plus a wide range of other solutes such as arsenite and antimonite. AQP7 is also 
permeable to these trivalent versions of the toxic metalloids, arsenic and antimony. (Carbrey, 
2009)  
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1.3. Aquaporinopathies – AQP-related human diseases 
AQPs are extensively expressed in human body and play several roles in different physiological 
processes, such as the urinary concentrating mechanism, glandular secretion or skin hydration. 
AQP0, for example, being exclusively expressed in the eye lens, plays a central role in 
maintaining lens transparency. This water channel constitutes 60% of lens membrane proteins 
and, when absent, leads to the development of cataracts in humans and mice. (Ishibashi, 2009) 
Although there is still much to learn on the pathological processes arising from AQPs mutations 
or dysfunction, several unexpected pathologies have already been associated with/or attributed 
to the impaired function of water channels. Among them are brain edema, epilepsy, obesity, 
diabetes and cancer, where AQPs play unpredictable roles. (Verkman, 2009) 
 
1.3.1. AQPs in cancer 
Until 2008, twelve different tumor cell types in humans and mice were reported to express 
AQPs and for the majority, histological tumor grade showed a positive correlation with AQPs 
expression levels. (Verkman, 2008) 
As shown in Table 1.2, several AQPs are found in different tumor types. Among them is AQP1, 
which is strongly expressed in tumor microvessels (Endo, 1999; Vacca, 2001), with an 
impressive presence in several cancers. 
 
 Table 1.2. AQP expression in different human tumors. Modified from (Verkman, 2008). 
Tumor type AQP Expression 
Glioma AQP1, 3, 4, 5, 9 ↑ 
Laryngeal cancer AQP1 ↑ 
Lung adenocarcinoma AQP1, 3 ↑ 
Renal cell 
AQP1 
AQP3 
↓ 
↑ 
Colorectal 
AQP1,3,5 
AQP8 
↑ 
↓ 
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1.3.1.1. AQP-facilitated cellular migration 
Studies with AQP1-null mice for investigation of a possible role of AQP1 in tumor 
angiogenesis, revealed a lower density of microvessels and consequently, an impaired 
angiogenic process. The overall result was a slowed tumor growth and improved survival. Other 
studies with AQP1-null mice reported a remarkable impairment in cellular migration, 
suggesting a strong correlation between AQP1 overexpression and migration. (Verkman, 2005) 
The same authors proposed a three step mechanism for AQP-facilitated cell migration, 
regardless of the cell type and AQP isoform (Verkman, 2008), as shown in Figure 1.4. 
In the first step of cell migration, actin is cleaved leading to transient formation of membrane 
protrusions (lamellipodia and membrane ruffles). Ion uptake occurs at the tip of a 
lamellipodium (anterior end of the cell) creating local osmotic gradients. Consequently, a rapid 
water influx occurs increasing the local hydrostatic pressure, leading to the expansion of the cell 
membrane. If present, AQP polarizes to the leading edge of the cell membrane, facilitating 
water influx. Finally, actin repolymerizes leading to the stabilization of the protrusion. 
(Verkman, 2011a) 
 
 
Figure 1.4. Proposed mechanism of AQP-facilitated cell migration. Water entry into protruding 
lamellipodia in migrating cells. Modified from (Verkman, 2012). 
 
When expressed in tumor cells, AQP increases their ability to extravasate across blood vessels 
and to invade local tissues. (Hu, 2006) AQP-facilitated cell migration thus appears to be 
important not only in angiogenesis but also in tumor cell metastasis and spread. These findings 
may explain the high expression levels of AQPs in different tumor types and the correlation 
between AQP expression levels and tumor grade. (Verkman, 2012)  
It must be noted that even non-orthodox AQPs are able to transport water. 
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1.3.1.2. AQP3 in skin tumorigenesis 
AQP3 is an aquaglyceroporin widely expressed in many human tissues. Recently, analysis of 
AQP3-knockout mice has provided interesting information on the glycerol transport through 
this channel. In addition, different skin pathologies have been associated to AQP3 
misexpression, namely skin cancer. (Hara-Chikuma, 2008a,b) 
Mammalian skin is composed by three different layers, as shown in Figure 1.5A. The deepest 
layer of skin is rich in adipocytes. Above lies the dermis, rich in capillaries and composed by 
collagen fibers and elastin (among other components), that acts as a support layer for the third 
and most superficial skin layer, the epidermis. This region contains several different cell layers, 
being the external layer the stratum corneum (SC), that consists in terminally differentiated 
keratinocytes. These cells provide the outermost barrier against loss of body ﬂuids. Thus, 
adequate hydration of the SC is essential for the maintenance of the skin health, allowing its 
ﬂexibility and decreased vulnerability to external aggressions. (Rojek, 2008)  
In mammalian skin, AQP3 is strongly expressed at the basal membrane of keratinocytes (Figure 
1.5B). Studies with hairless mice lacking AQP3 exhibit reduced SC hydration (Verkman, 2005), 
reduced skin elasticity, delayed wound healing and delayed biosynthesis of SC (after removal 
by tape-stripping) (Hara, 2002). Studies using AQP3-null mice have also shown that water 
transport through AQP3 is not a rate-limiting factor in the trans-epidermal water loss. 
(Verkman, 2005) 
 
Figure 1.5. Reduced skin hydration in AQP3 deficiency. A| Schematic representaion of skin layers;   
B| Proposed mechanism of AQP3 function in the skin. Modified from (Verkman, 2005). 
 
The AQP3 deficiency in the skin reflects reduced epidermal glycerol permeability and reduced 
glycerol content in SC and epidermis, while normal glycerol content in serum and dermis. Thus, 
a reduced glycerol transport from blood into the epidermis, through the basal keratinocytes, is 
pointed as the plausible responsible for the skin phenotype in AQP3-null mice. (Verkman, 
2005)  
A| B| 
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More recently, studies in mice with disrupted AQP3 gene, revealed reduced epidermal pools of 
glycerol, glucose and ATP. (Hara-Chikuma, 2008b) Hara-Chikuma and co-workers also found a 
positive correlation between glycerol and ATP content in AQP3
+/+
 mice keratinocytes, 
suggesting the involvement of AQP3-mediated glycerol transport in ATP synthesis. This fact, 
together with a positive correlation between ATP content and cell proliferation, brought new 
clues about the importance of AQP3 in states of epidermal hyperproliferation, such as psoriasis, 
atopic dermatitis, wound healing, ichthyosis and even tumorigenisis, where it is upregulated. 
Summarizing, AQP3 plays central roles in skin hydration, wound healing and tumorigenesis 
(Hara-Chikuma, 2008b,c) although the implicit mechanism of tumorigenesis resistance 
observed for AQP3-null phenotype is still not clear. Figure 1.6 illustrates the proposed pathways 
for AQP3-dependent skin hydration, wound healing and AQP3-dependent cell proliferation 
during skin tumorigenisis. According to this mechanism, the overexpression of AQP3 leads to 
an increased glycerol uptake. As a rich energetic substrate, a high glycerol pool leads to 
increased ATP synthesis and, consequently, cell proliferation. Notwithstanding, and regarding 
AQP3 in particular, the triggering pathway for tumorigenesis is still obscure. 
 
 
Figure 1.6. Schematic representation of the proposed mechanisms of AQP3-dependent skin 
hydration, wound healing, and tumorigenesis. Modified from (Hara-Chikuma, 2008c; Verkman, 2009). 
 
It must be noted that in 2012, Gao and co-workers described the contribution of AQP3 to the 
chemoresistance of melanoma to arsenite. (Gao, 2012) In addition, other studies identified an 
unexpected permeant for AQP3, the hydrogen peroxide (Miller, 2010; Bertolotti, 2013). This 
fact may unravel new unexpected roles for AQP3 in tumor biology through oxidative stress.  
 
 
(For recent reviews of the roles of AQPs in Medicine see: (Verkman, 2012,2013)) 
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1.4. AQP inhibitors: pharmaceutical opportunities  
Several pathologies have been associated and/or attributed to the impaired functioning of AQPs. 
Consequently, the potential utility of aquaporin modulators for the treatment of several 
pathologies such as kidney diseases, obesity, glaucoma, brain edema, epilepsy and cancer 
should be considered. (Verkman, 2009)  
As an example, AQP1-null xenograft models of subcutaneous melanoma tumors showed 
decreased tumor growth and reduced angiogenesis when compared to wild-type controls. These 
observations were associated with AQP1 gene disruption. (Lopez-Campos, 2011; Machida, 
2011) Moreover, a chemical down-regulation of AQP1 expression was reported to block 
angiogenesis and tumor growth. (Bin, 2011) 
Due to the central roles of AQP3 in epidermal cell migration and proliferation (Hara-Chikuma, 
2008b,c) this aquaglyceroporin can also be seen as a potential target for cancer therapy. 
Recently, AQP3 inhibition by copper(II) ions reduced cell growth rates and increased the 
therapeutic efficacy of Cisplatin. (Huber, 2012) 
Therefore, pharmacotherapy via AQP modulation should be considered as a valuable strategy 
for treating several and different human diseases. Despite AQP-based therapy for human 
diseases still being considered a distant reality, recent progresses were achieved with AQP4 in 
neuromyelitis optica. (Verkman, 2011b; Huber, 2012) 
 
 
1.4.1. Metal-based agents as AQP3 inhibitors 
Recently, gold complexes were described as new potent inhibitors of AQP3, being four times 
more effective, for the same concentration, than the common mercurial compounds used for 
AQP inhibition studies in vitro. (Martins, 2012)  
In 2012, Martins and co-workers reported [Au(phen)Cl2]Cl (phen= phenantroline, Auphen) and 
[Au(dien)Cl]Cl2 (dien= diethylendiamine, Audien) as potent and highly selective inhibitors of 
the glycerol transport in human RBCs (90% inhibition) with half-inhibitory concentration (IC50) 
values in the low-micromolar range. In addition, these Au(III) compounds showed to be non-
toxic in RBC during the time span of channel inhibition. Their water solubility, plus the 
previous considerations, makes them suitable drugs for in vivo studies. (Martins, 2012) More 
recently, the same group tested other Au(III) compounds as AQP3 inhibitors. In order to 
evaluate and compare the influence of metal substitution on the inhibitory potency, the Cu(II) 
compound Cuphen was also tested.  
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As result, the following compounds were also identified as potent and selective AQP3 
inhibitors: [Cu(phen)Cl2]Cl (phen= phenantroline, Cuphen), [Au(terpy)Cl]Cl2 (terpy = 
terpyridine, Auterpy), [Au(bipy(R,R’))Cl2]PF6 (bipy = bipyridyl) where R=R’= H, Me, NH2 
(Aubipy, AubipyMe, AubipyNH2 respectively). (Martins, 2013)  
Figure 1.7 displays the structures of several metallodrugs described as AQP3 inhibitors. 
 
 
Figure 1.7. Structures of several metallodrugs described as AQP3 inhibitors by Martins and 
colleagues. Modified from (Martins, 2013). 
 
At this point, it is interesting to refer that all of these gold complexes were already described as 
antiproliferative agents in vitro, being considered as promising candidates to anticancer drugs. 
(Messori, 2000; Casini, 2009; Serratrice, 2012)  
  
 
1.4.2. Metallodrugs as antitumoral agents 
Metal compounds have been widely used in medicine for several decades. Among them we can 
find bismuth (anti-ulcer), silver (anti-microbial) and iron (anti-malarial) compounds and, in 
terms of anti-tumor activity, the earliest reports date from the sixteenth century. (Desoize, 2004) 
In the 1960s, B. Rosenberg discovered a platinum-based compound – cisplatin - with antitumor 
activity (Rosenberg, 1965, 1969), which became approved by the FDA in 1978 and still 
continues to be the first line of treatment for some types of cancer. (Guidi, 2012) Thus, 
metallodrugs are still a promising research area, drawing increased attention within the 
medicinal chemistry communities due to their antiproliferative and antitumor properties, 
obtained in both in vitro and in vivo studies. (Nobili, 2010; Berners-Price, 2011) 
Since 1890, when Robert Koch discovered that gold cyanide was able to inhibit the growth of 
M. tuberculosis, gold compounds started to be developed as therapeutic agents. (Benedek, 2004) 
In the mid 1980s, auranoﬁn, an orally active Au(I) which was approved for rheumatoid arthritis 
treatment, was described as an inhibitor of tumor cells growth in vitro. (Mirabelli, 1985)  
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This was the beginning of a great advance in medicinal inorganic chemistry and metal-based 
compounds started to gain relevance in this field. This fact is due to the variety of properties 
that metal-based compounds can present like the coordination number, redox state or different 
geometries in addition to the intrinsic properties of the metal ion itself, dictating alterations in 
the compound reactivity. 
By this time, Cisplatin was already marketed and Au(III) compounds, with square planar 
geometry, were seen as possible mimetics, since they present the same electronic configuration. 
The AQP3 inhibitors described above, including the Au(III), are examples of metallodrugs with 
cytotoxic activity. It is important to highlight that several Au(III) compounds are already 
described as being more potent than Cisplatin, overcoming the recurrent resistance problems 
associated to this chemotherapeutic. (Messori, 2000) 
Despite the cytotoxic potential presented by metallodrugs, and in particular Au(III) compounds, 
this type of compounds have some drawbacks, namely instability under physiological 
conditions. As reactive molecules, they present high hydrolysis rates and reduction potential 
giving rise to the need of an adequate stabilization of these drugs at oxidation state +3. 
(Messori, 2004) 
Several efforts have been made in order to synthesize gold complexes with increased stability 
under physiological conditions for pursuing Au(III) potential in cancer therapy. One approach 
consists on the stabilization of the metal center by nitrogen donors, to which Au(III) shows 
preference. Examples are Auphen and Auterpy (see Figure 1.7). (Nobili, 2010) Regarding 
Au(III) reactivity, it is also important to consider the variety of biological targets that this class 
of compounds may have in vivo. Human RBCs, in which glycerol movement across membranes 
is mostly mediated by AQP3, constitute a good example. (Martins, 2013) 
In order to minimize the drawbacks mentioned above (i.e. drug instability and reactivity) 
appropriate carriers must be designed. In addition to a possible protection of the drug from 
inactivating events in vivo, an ideal carrier, among other characteristics, should be 
biocompatible and improve the therapeutic index of the associated compound. 
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1.5. Drug Delivery Systems (DDS) 
For the last decades, several efforts have been made pursuing the improvement on 
pharmacokinetic, biodistribution and pharmacodynamic profiles of drug candidates, which in 
the free form, present pharmaceutical properties far from the ideal. 
As briefly referred above, a drug carrier should provide the release of the drug within the 
therapeutic window at the site of action, must be biodegradable and/or easily excreted after 
exerting its therapeutic effect, should present low immunogenicity and prevent premature 
degradation of the drug. Ideally, it should also be stable upon storage and present low 
production costs. (Gaspar, 2008) 
Regarding cancer therapy, and particularly solid tumors, the DDS should also provide the ability 
to penetrate into the tumor interstial space. Based on these previous considerations, the reason 
of nanotechnology growth in the recent years is evident. Within this area, and gathering all the 
properties of an ideal DDS, liposomes are considered one of the most promising and successful 
drug carriers for cancer therapy. (Allen, 2004) 
 
 
1.5.1. Liposomes 
Liposomes were described for the first time by Dr Alec D. Bangham roughly 50 years ago. 
(Bangham, 1965) These systems were firstly developed as models of biological membranes due 
to their architecture that mimics the molecular structure of natural cell membranes. As an 
example, the identification of the first AQP was performed after protein reconstitution into 
liposomes in 1992. (Zeidel, 1992) 
In the 70’s, these lipid systems started to be used for drug delivery (Gregoriadis, 1972) and 
nowadays, several liposomal formulations are already available in the clinic or in advanced 
development stages, for treatment of different pathologies including cancer. (Slingerland, 2012) 
These vesicles may present mean sizes ranging from few nanometers (50 nm) to more than 1 
µm, and are colloidal particles generally constituted by naturally occurring phospholipids and 
cholesterol, conferring biodegradability properties. These spherical vesicles are organized in 
bilayers, separated by aqueous compartments, mimicking cellular membranes, and possessing 
the ability to incorporate different substances/compounds independently of their properties such 
as molecular weight, solubility or charge. (Cruz, 2009) 
Due to the liposomes typical structure, they are able to encapsulate/incorporate molecules with 
distinct properties, which is an advantage per se. Hydrophilic molecules can be entrapped in the 
aqueous compartments while compounds with hydrophobic properties can be partial or totally 
accommodated within the lipid bilayers, as shown in Figure 1.8A. (Bei, 2010) 
Liposomes can be designed aiming therapeutic, diagnostic and even imaging purposes. 
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Figure 1.8. Liposomes – versatile structures. A| classic liposomes with hydrophilic drug (a) at the inner 
aqueous compartment and hydrophobic drug (b) within the lipid bilayer. B| Immunoliposomes possess 
specific antibodies (or antibody fragments) at surface to enhance a specific targeting. C| Long-circulating 
liposomes present modified surface by the presence of polymers such as PEG (c) that allows the increase 
of circulation time in bloodstream and protects the carrier from opsonizing proteins (d). D| Long-
circulating immunoliposome. Adapted from (Torchilin, 2005). 
 
 
Focusing on their therapeutic action, liposomes as DDS present several advantages over non-
encapsulated drugs.  
 
In addition to the fact that liposomes are able to entrap a therapeutic molecule in their structure, 
several other advantages should also be mentioned. Liposomes are able to enhance drug 
solubility and to protect the incorporated drug from premature degradation or metabolization, 
while keeping its therapeutic activity, affording to a partial reduction of possible side-effects in 
healthy tissues and/or organs. Moreover, liposomes present a high versatility. They can be 
constructed according to the physicochemical properties of each particular drug or to the desired 
target tissue or organ. This may be performed by i) varying the lipidic constituents, ii) changing 
bilayer rigidity, iii) adding surfactants to lipid composition to alter superficial charge and, 
consequently, their stability and/or interaction with affected cells or organs, iv) attaching 
different polymers as shown in Figure 1.8C (such as PEG) to enhance the half-time of the 
vesicle in bloodstream and, consequently, of the drug and even iv) including antibodies or 
antibody fragments at the liposome surface for a specific targeting, as shown in Figure 1.8B and 
D. (Torchilin, 2005, 2007; Cruz, 2009) 
 
 
 
 
c 
d 
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From all above mentioned advantages, the most important strength of these systems is their 
ability to improve pharmacokinetics (PK) and biodistribution (BD) of the associated 
therapeutics. Liposomes, depending on their lipid constituents, are able to increase the 
circulation in the bloodstream of the incorporated drug reducing its clearance. This type of lipid 
vesicles is designed as long-circulating liposomes (LCL) and they may be constructed by 
inclusion in the lipid composition of different polymers, covalently linked to phospholipids. 
Polyethylene glycol (PEG) is the most popular polymer used. (Harris, 2003) The presence of 
PEG at liposome surface, as shown in Figure 1.8C, reduces the adsorption of plasma proteins. 
Due to these characteristics, this type of liposomes, after parenteral administration, is able to 
have a longer circulation time in bloodstream. Regarding BD, alterations can occur via the so 
called enhanced permeability and retention (EPR) effect, also called passive targeting. (Maeda, 
2000, 2001) Several pathological conditions present increased permeability of tissue 
vasculature. Solid tumors are a good example of compromised vasculature. As tumor tissue 
starts to grow, the support of nutrients and oxygen will eventually be insufficient for tumor 
nutritional requirements. To overcome this situation, cytokines and other signaling molecules 
are released from tumor cells in order to recruit more blood vessels in a process called 
angiogenesis. Angiogenic blood vessels present gaps of 600 to 800 nm between adjacent 
endothelial cells (Figure 1.9) allowing the extravasation of liposomes to the interstitial space in 
a size-dependent manner.  
 
Figure 1.9. Extravasation and accumulation of liposomes in tumor tissue due to EPR effect. 
(Saetern, 2004) 
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As these lipid systems present sizes substantially lower, they tend to accumulate in the tumor 
tissue. Thus, to take advantage of this EPR effect, liposomes must present long circulation times 
in the bloodstream (by the inclusion of PEG in lipid composition, for example) in order to 
enable, to a higher extent, the extravasation of the drug into the tumor.  
In addition to the preferential targeting of liposomes to tumor vasculature, it is important to 
refer that, in general, tumor tissues lack an effective lymphatic drainage. Therefore, extravasated 
liposomes are able to accumulate in tumor tissues. (Allen, 2004; Torchilin, 2007; Cruz, 2009) 
All of these characteristics, combined with the already mentioned biodegradability, make 
liposomes a suitable and promising carrier for clinical use and, particularly, for cancer therapy.  
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1.6. Aims and goals 
In the present study the first objective was to validate the cytotoxicity of a small library of 
metallodrugs, already described as AQP3 inhibitors. Based on the cytotoxic screening, one 
compound was selected to be further incorporated in an adequate delivery system, liposomes. 
The second objective of the work was the design and development of liposomal formulations 
able to incorporate the selected compound. The third objective was the in vitro evaluation of the 
cytotoxic activity of the AQP3 inhibitor previously selected, both in the free and in the 
liposomal forms, in two cancer cell lines.  
 
In order to fulfill the objectives of the present thesis the work was persecuted according to the 
following: 
1. Validation of cytotoxicity of a small library of metallodrugs already described as AQP3 
inhibitors against a human epidermoid carcinoma cell line (A431) overexpressing this 
aquaglyceroporin; 
2. Selection of a single compound to be incorporated in liposomes, based on the cytotoxic 
activity against A431 cells; 
3. Establishment of an adequate methodology for quantification of the selected AQP3 
inhibitor; 
4. Development and characterization of liposomes incorporating the AQP3 inhibitor. In 
particular, the influence of lipid composition, mean size and superficial charge on 
incorporation parameters were studied; 
5. Cytotoxic in vitro studies of the selected metallodrug formulations in free and liposomal 
forms against two cancer cell lines: the A431 and the murine colon cancer cell line, 
C26. 
 
It is important to highlight that, due to similarities of the metallodrugs tested, the developed 
formulation can be seen as a model for further studies involving other AQP3 inhibitors. 
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2.1. Materials 
All the metallodrugs were synthesized and gently provided by Dr. Angela Casini 
(Pharmacokinetics, Toxicology and Targeting, Research Institute of Pharmacy, University of 
Groningen). 
Six mononuclear compounds were included in the present work: [Au(phen)Cl2]Cl (phen=1,10-
phenantroline, Auphen), [Cu(phen)Cl2]Cl (Cuphen) [Au(dien)Cl]Cl2 (dien = diethylentriamine, 
Audien), [Au(terpy)Cl]Cl2 (terpy = tripyridine) and two different compounds based on the 
following [Au(bipy(R,R’))Cl2]PF6 (bipy = 2,2’-bipyridine, Aubipy), where R=R’= H, or Me. 
Aubipy compounds will be referred according to the substituent group:. R=Me, AubipyMe, 
R=H, Aubipy. 
 
The pure phospholipids, egg phosphatidylcholine (PC), dimyristoyl phosphatidylcholine 
(DMPC), Dipalmitoyl phosphatidylcholine (DPPC) and distearoyl phosphatidylethanolamine 
covalently linked to poly(ethylene glycol) 2000 (PEG), used for the preparation of liposomal 
formulations were purchased from Avanti Polar Lipids (Alabaster, AL).  
Deionized water (Milli-Q system; Millipore, Tokio) was used in all experiments. Nuclepore 
Track-Etch Membranes were purchased from Whatman Ltd, (NY, USA). Culture media and 
antibiotics were obtained from Invitrogen (Life Technologies Corporation, NY, USA). Reagents 
for cell proliferation assays were purchased from Promega, (Madison, WI, USA). 
Octadecylamine (n-Stearylamine (SA)), cholesterol (Chol) and Hoescht 33258 were purchased 
from Sigma (Sigma-Aldrich, St. Louis, MO, USA). All the remaining chemicals and substrates 
used were of analytical grade. 
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2.2. Methods 
2.2.1. Preparation of Cuphen liposomal formulations  
Liposomes composed of the selected phospholipids were prepared by the dehydration-
rehydration method (DRV) (Cruz, 1993; Gaspar, 1996, 2008). Briefly, the selected 
phospholipids (20µmol/mL) were dissolved in chloroform and the mixture was dried by rotary 
evaporation (Buchi, Switzerland) of the organic solvent to obtain a thin film in a round-bottom 
flask. The film was then dispersed in a Cuphen solution, frozen (-70ºC) and lyophilized (Freeze 
dryer, Edwards, USA) overnight.  
The rehydration of the lyophilized powder was performed with a buffer constituted of 10 mM 
HEPES and 145 mM NaCl, pH 7.4 (HEPES buffer) in two steps, in order to enhance the 
Cuphen incorporation (Lasch, 2003): first, a 30 minute step where two-tenth of the original 
dispersion was added, and subsequently, the addition of the remaining volume (up to the 
starting volume). Here it is important to refer that the hydration steps should always be 
performed at a temperature above the phase transition temperature (Tc) of the phospholipids. 
In order to reduce and homogenize the mean size of liposomes, the so formed vesicles were 
submitted to an extrusion step through polycarbonate membranes of appropriate pore size until 
the desired vesicle size is reached (1, 0.8, 0.6, 0.4 (3x), 0.2 (3x) and 0.1 (3x) µm) under nitrogen 
pressure (10-500 lb/in
2
) with an Extruder device (Lipex: Biomembranes Inc., Vancouver, 
British Columbia, Canada).  
The separation of non incorporated Cuphen was performed by ultracentrifugation at 250,000 g 
for 120 min at 15ºC in a Beckman LM-80 ultracentrifuge (Beckman Instruments, Inc, USA.) 
Finally, the pellet was ressuspended in HEPES buffer, according to the final concentration 
desired. 
 
 
2.2.2. Characterization of Cuphen liposomal formulations  
Liposomes were characterized in terms of lipid composition, lipid (Lip) and Cuphen 
concentration, mean diameter, zeta potential and by the following incorporation parameters: 
initial and final Cuphen to lipid ratios [(Cuphen/Lip)i and (Cuphen/Lip)f, respectively] and 
incorporation efficiency (I.E.) defined as the percentage of [(Cuphen/Lip)f]/[(Cuphen/Lip)i]. 
The I.E., being a ratio between final to initial (Cuphen/Lip), determines the ability that a 
particular lipid mixture presents for incorporating Cuphen in liposomal matrix.  
 
 
 
2. Materials and Methods 
 
25 
 
2.2.2.1. Cuphen quantification 
UV/Vis spectroscopy, due to its simplicity and reliability was the selected technique for Cuphen 
quantification. Moreover, the destruction of liposomes was performed by addition of absolute 
ethanol (EtOH). 
From a stock solution of 200nmol/mL in EtOH, serial dilutions were performed with the same 
organic solvent and UV spectra were traced (220nm-800nm) in a UV/Vis spectrophotometer 
(Shimadzu UV 160A). 
After selection of the appropriate wavelength, calibration curves were performed in order to 
evaluate the relation between the absorbance values and concentration. The selected 
concentrations ranged from 2 μM up to 20 μM, in order to ensure linearity and enabling the 
determination of Cuphen content in developed formulations after liposome disruption with 
EtOH.  
 
 
2.2.2.2. Phospholipid quantification 
The method for phospholipid quantification was based on the colorimetric determination of 
phosphate (PO4). In the presence of ammonium heptamolybdate ((NH4)6Mo7O24.4H2O) the 
inorganic phosphate was converted to phosphomolybdic acid, which was quantitatively 
converted to a blue color due to reduction of ascorbic acid during heating, using the method 
described by Rouser and co-workers (Rouser, 1970). Briefly, samples (in triplicate) containing 
phosphate quantities between 20 and 80 nmol (sample volume below 100 µL) were pipetted into 
15 mL glass tubes. In parallel, a calibration curve from a 0.5 mM phosphate solution was 
prepared: in triplicate, phosphate amounts of 20, 30, 40, 50, 60 and 80 nmol were pipetted into 
glass tubes. All tubes were heated (180ºC) in a heating block until dryness. After cooling, 0.3 
mL of perchloric acid (70-72%) was added to all tubes. In order to avoid volume losses, marbles 
were placed on the top of all glass tubes. At this point, all tubes were heated in the heating block 
(180ºC) for 45 min, to convert all the organic lipid phosphate to the inorganic form and until 
achievement of a clear solution. After cooling samples to room temperature, 1.0 mL of H2O, 0.4 
mL of hexa ammonium heptamolybdate solution [1.25% (w/v)] followed by 0.4 mL of ascorbic 
acid solution [5% (w/v)] were added to all glass tubes. A blue color solution was obtained due 
to the reduction of ascorbic acid during heating in a boiling water bath for 5 min. After cooling, 
the absorbance of all samples was recorded (797nm) in a UV-mini 1240 Spectrophotometer 
(Shimadzu). The amount of phosphate in samples was obtained through the calibration curve 
with the aid of linear regression. The calibration curve was linear up to absorbance values of 
around 1.000. 
-
³ 
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2.2.2.3. Liposome size measurements  
Liposome mean diameter was determined by dynamic light scattering based on Brownian 
motion of the particles in a hydrodynamic sizing system (Zetasizer Nano S (Zen 1600), Malvern 
Instruments, UK). For viscosity and refractive index, the values of pure water were used. As a 
measure of particle size distribution of the dispersion, the system reports the polydispersity 
index, (P.I.). P.I. ranges from 0.0, for an entirely monodisperse sample, up to 1.0 for a 
polydisperse suspension. To determine the mean diameter and P.I. of liposomal preparations, 
samples were diluted to a final lipid concentration of 0.2 µmol/mL in HEPES buffer. All the 
measurements were done in an appropriate polycarbonate cell at a temperature of 25ºC. 
All liposomal formulations were prepared in order to obtain a P.I. < 0.30. 
To ensure that appropriate mean diameter and P.I. were achieved, these parameters were also 
determined during the extrusion procedure. 
 
 
2.2.2.4. Zeta potential determination  
Zeta potential of liposomal formulations was measured in a hydrodynamic sizing system 
(Zetasizer Nano Z (Zen 2600), Malvern Instruments, UK). Zeta potential is defined as an 
electric potential between the membrane surface and the ionic dispersion medium. Zeta 
potential was measured using a combination of the measurement techniques: Electrophoresis 
and Laser Doppler Velocimetry, sometimes called Laser Doppler Electrophoresis. This method 
measures how fast a particle moves in a liquid when an electrical field is applied. For viscosity 
and refractive index, the values of pure water were used.  
Before determination of the zeta potential of liposomal formulations, an initial check of the 
apparatus was made with a standard known zeta potential value (standard DTS5050, Malvern 
Instruments, Ltd., UK). Dilutions of liposomal formulations were made in HEPES buffer, at a 
final lipid concentration of about 0.2 µmol/mL. Samples were slowly introduced into a clear 
disposable zeta cell with a syringe to avoid air bubbles. The zeta potential of samples was 
recorded at a temperature of 25ºC.  
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2.2.2.5. Stability of Cuphen liposomes  
The stability in suspension of Cuphen liposomes was assessed by quantifying Cuphen and lipid 
contents after storage at 4ºC for 10 days.  
After this storage period (t=10), samples were taken (t=0), diluted in HEPES buffer and 
submitted to a centrifugation step (250,000 g for 120 min at 15ºC). Liposomes were 
ressuspended in HEPES buffer according to the initial volume. Cuphen and phospholipid 
contents were quantified. The stability was defined as the ratio in percentage between Cuphen to 
lipid ratio at t=10 and the initial Cuphen to lipid ratio at zero time (t=0), according to the 
following formula: [(Cuphen/Lip)t=10/(Cuphen/Lip)t=0] x 100. 
In addition, vesicles mean size and zeta potential were also determined. 
 
 
2.2.3. Cell Culture 
Human epidermoid carcinoma cells, A431, gently provided by Prof. Eschevarria (Instituto de 
Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Seville, Spain) were 
seeded in culture flasks and maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) with 
high-glucose (4500 mg/L), supplemented with 10% fetal bovine serum (FBS) and 100 μg/mL 
penicillin/streptomycin. Murine colon cancer cells, C26, obtained from CLS (Cell Lines 
Service, Life Technologies) were plated in culture flasks and maintained in Roswell Park 
Memorial Institute (RPMI) 1640 with the supplementation described above. Both cell lines were 
kept at 37° C under a 5% CO2
 
atmosphere. Maintenance of cultures was performed every 
two/three days, until cells reached a confluence of about 80%. At this point, sub-culturing was 
performed using a solution of TrypLE (Invitrogen, Life Technologies Corporation, NY, USA). 
Briefly, after media removal, the cell layer was washed with phosphate buffered saline (PBS) 
and incubated with TrypLE for 7-10 minutes at 37ºC. After cells detachment, complete growth 
medium was added. The cells were then centrifuged in a bench centrifuge (Beckman, Izasa, 
Spain) at 500g for 10 min and the pellet ressuspended in fresh culture medium. Appropriate 
aliquots of the cell suspension were seeded in new culture flasks. 
Cell storage was done in liquid nitrogen, in cryotubes with freezing medium consisting of FBS 
and 10% dimethylsulfoxide (DMSO). 
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2.2.4. Evaluation of cellular viability 
2.2.4.1. Hoechst Staining 
Hoechst labeling of attached cells stains chromatin and can be used to detect apoptotic nuclei by 
morphological analysis. 
A431 cells were seeded (10
5 
cells/mL) in 35mm dishes and incubated with 5, 15 and 50 μM of 
each of the gold compounds – Auphen, Auterpy, Audien, Aubipy and AubipyMe, for 24 and 
48h. At each time point, culture medium was gently removed to prevent detachment of cells. 
Attached cells were fixed with 4 % paraformaldehyde in PBS, pH 7.4, for 10 min at room 
temperature, washed with PBS, incubated with Hoechst dye 33258 (Sigma-Aldrich Corp.) at 5 
μg/mL in PBS for 5 min, washed with PBS, and mounted using Fluoromount-GTM 
(SouthernBiotech, Birmingham, AL, USA). Fluorescence was visualized using an Axioskop 
fluorescence microscope (Carl Zeiss GmbH, Jena, Germany). Blue-fluorescent nuclei were 
scored blindly and categorized according to the condensation and staining characteristics of 
chromatin. Normal nuclei showed non-condensed chromatin disperse over the entire nucleus. 
Apoptotic nuclei were identified by condensed chromatin, contiguous to the nuclear membrane, 
as well as by nuclear fragmentation of condensed chromatin. Five random microscopic fields 
per sample of approximately 150 nuclei were counted and mean values expressed as the 
percentage of apoptotic nuclei. 
 
 
2.2.4.2. Trypan Blue assay 
The trypan blue exclusion method was used to evaluate total cell death. Trypan blue is a cell 
stain that only permeates non-viable cells; i.e. cells whose permeability is somehow 
compromised. 
This assay was performed in parallel with the Hoechst staining: briefly, the media/supernatant 
was removed from 35mm dishes and centrifuged at 600g for 4 minutes. The cell pellet was 
ressuspended in 10μL of Trypan Blue 0.4%. Dead cells (stained) were counted under a 
brightfield microscopy (Carl Zeiss GmbH, Hamburg, Germany).  
 
 
2.2.5. MTS assay 
CellTiter 96®AQueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, USA) is 
a ready-to-use mix of substrates which allows the measurement of the metabolic activity of 
viable cells by reduction of a tetrazolium salt. Briefly, dehydrogenase enzymes found in 
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metabolically active cells convert the tetrazolium compound (inner salt; MTS) to a water 
soluble formazan dye, which can be quantified spectrophotometrically - absorbance measured at 
490nm and directly correlated to viable cells number. (Cory, 1991; Riss, 1992). The assay was 
performed according to manufacturer’s instructions.  
 
 
2.2.5.1. Metallodrugs cytotoxicity screening 
Briefly, A431 cells were seeded in 96-well plates (100 µL; 10
5 
cells/mL) for 24h. Stock 
solutions of metallodrugs were prepared in Milli-Q water. Cells were incubated with each 
metallodrug at concentrations ranging from 0.25 µM to 60µM for 48h and 72h. All the 
experiments were performed in triplicate. At each timepoint, the media was removed and 
replaced with fresh media. Subsequently, 20 µL of MTS were added to each well, plates slightly 
agitated and incubated, under the same culture conditions mentioned above. Absorbance was 
measured 60, 90 and 120 min after MTS addition, at 490nm in a BioRad microplate reader 
Model 680 (Bio-Rad, Hercules, CA). 
 
 
2.2.5.2. Cytotoxic effect of Cuphen formulations against cancer cells 
For these procedures, a Cuphen stock solution of 500nmol/mL was prepared in PBS and filtered 
through a sterile syringe filter (0.20 µm). From the stock solution, different dilutions were 
performed with the respective culture medium according to the desired concentrations for each 
experiment.  
For the determination of the cytotoxic effects of free and liposomal Cuphen, 7.5 x 10
4
 cells/mL 
were used for both A431 and C26 cells. (Calado, 2012)  
Cells were plated in 96-well plates (200 µL) under the culture conditions described above (see 
2.2.3 Cell Culture). Twenty-four hours after plating, medium was removed and adherent cells 
were treated with Cuphen in the free or in the liposomal form, with concentrations ranging from 
0.625 μM to 50 µM (100 µL of the respective dilution per well). Three different incubation 
periods were tested (48h, 72h and 96h). 
Negative control was constituted by the cell line under study in the presence of the culture 
medium. Unloaded liposomes also constituted another control group, using the same lipid 
concentrations as in loaded liposomes. 
All tests were performed with six samples for each concentration under study. 
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2.2.6. Statistical analysis 
All data presented are expressed as mean ± standard deviation (S.D.) with the exception of the 
cytotoxicity results (i.e. IC50 values). For this last case, data is presented as the best fit value ± 
standard error (S.E.). Statistical analysis was performed using the ANOVA One Single Factor. 
The acceptable probability for a significant difference between mean values was p<0.05. 
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3.1. Metallodrugs cytotoxicity screening  
In order to select a unique metallodrug for incorporation into liposomes, trypan blue assay, 
Hoechst staining and the MTS assay were performed with a small library of metallodrugs, 
previously described as AQP3 inhibitors, using the A431 human epidermoid carcinoma cell 
line. 
 
3.1.1. Trypan Blue assay and Hoechst staining 
A431 cells were incubated with Auphen, Auterpy, Audien, Aubipy or AubipyMe for 24h 
(Figure 3.1) and 48h at different concentrations (5, 15 and 50 µM) and cell death analyzed using 
the trypan blue assay.  
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Figure 3.1. Cellular death induced by the different AQP3 inhibitors at 5, 15 and 50 µM (shown in 
ascending order), after incubation in A431 cells for 24h. Results are expressed as mean ± SD. 
*p<0.05; **p<0.01; ***p<0.001. 
 
At the higher concentration tested (50 µM) all of the compounds induced a significant increase 
in cell death (p<0.05). Nevertheless, only Auphen and Auterpy differed significantly from 
control at lower concentrations being thus, the most potent inducers of cell death (Figure 3.1). 
The most potent compounds were also tested after 48h of incubation with similar, although 
potentiated, results (data not shown). Results were also in accordance to those observed by 
Hoechst staining (data not shown). Of note, it was not possible to identify viable cells after 
incubation with the highest concentration (50 µM), when analyzing Hoechst staining. From this 
small library of metallodrugs, and based on previous results, Auphen aroused as the most potent 
inducer of cellular death, followed by Auterpy. Despite the modest results obtained for both 
Aubipy and Audien, only the last one was excluded from the library under study. It was 
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replaced by an analogue of Auphen, which was also described as a potent and selective inhibitor 
of AQP3 – Cuphen. (Martins, 2013) As result of this modification in the library under study we 
were able to infer about the role of the metal ion on the effects of these metallodrugs in cellular 
viability. 
 
 
3.1.2. MTS assay 
We continued our metallodrugs cytotoxicity screening using the MTS viability assay. A431 
cells were incubated with Auphen, Auterpy, Cuphen, AubipyMe and Aubipy in concentrations 
ranging from 0.250 µM up to 60 µM. 
These results allowed a deeper analysis on the cytotoxic effects induced by these compounds. 
Dose-response curves were traced for both incubation periods (Figure 3.2), with results obtained 
from the data fits being summarized in Table 3.1. 
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Figure 3.2. Concentration-dependent inhibition of A431 cellular viability by different metallodrugs 
after A| 48h and B| 72h of incubation. Results are expressed as mean percentage (%) of control ± SD. 
 
After 48h of incubation (Figure 3.2A) only Cuphen exerted sufficient cytotoxicity in order to 
decrease 50% of cellular viability. On the other hand, Aubipy did not exert any effect on the 
viability of this cancer cell line. By increasing the incubation time, the cytotoxicity of these 
compounds was potentiated. Figure 3.2B shows the dose-response curves obtained for Auphen, 
Cuphen, Aubipy and AubipyMe after an incubation period of 72h. Comparing the evolution of 
the curves it is possible to proceed with a double comparison. First, it can be observed that at 
50% of cellular viability, the concentration values for the phenantroline compounds (Auphen 
and Cuphen) are quite similar, suggesting a similar IC50 value. Both traces differ significantly 
for the one obtained for AubipyMe, where higher concentrations were needed to induce 50% of 
B| A| 
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cellular death. Second, Cuphen induces cellular death at a higher extension when compared to 
Auphen and AubipyMe, maintaining a cytotoxic profile very similar to the one obtained for the 
48h incubation period. This copper compound induces a decrease in cellular viability of 
approximately 80%, while Auphen is only capable of a 65% reduction. No curves were obtained 
for this range of concentrations and time of incubation for Auterpy and Aubipy. Aubipy was not 
able to exert any effect on the cellular viability even at the highest concentration of 60 µM and 
regarding Auterpy, a different range of concentrations should be considered. Thus, it was not 
possible to determine the IC50 values for these compounds.  
 
Table 3.1. Half-inhibitory concentrations for the cellular proliferation in A431 cells.  
Results obtained from three independent experiments. R2 - Average linear correlation coefficients obtained by data 
curve fits. 
 
 
Taken into account the results above, the cytotoxic potential of the studied metallodrugs, 
regarding this human epidermoid carcinoma cell line, can be represented in the following order: 
Cuphen > Auphen > AubipyMe. 
Regarding Cuphen and Auphen, it is worth observing that the similarity of their cytotoxic 
effects is justifiable by their analogue structures, differing only in the metal core. In 1996, 1,10-
phenanthroline was described as an inducer of DNA fragmentation in isolated rat-liver nuclei. 
Thus, cytotoxic effects can also be attributed to this complexing agent (Burkitt, 1996) in 
addition to the metal ion, which affords for the differences in cytotoxic activity between these 
two compounds.  
Based on the above results, Cuphen was the molecule chosen to pursue in the present thesis. In 
addition to the high cytotoxic effect in A431 cells, it is important to refer that copper-
phenantroline complexes are being described since 1979 as potent inducers of oxidative DNA 
damage. (Sigman, 1979, 1996; Bales, 2005) and Cu(II) ions are already described in literature 
as inhibitors of AQP3. (Zelenina, 2004) Moreover, this metallodrug is constituted by a metal ion 
which is physiologically accepted turning Cuphen as a very promising molecule to be further 
tested in a murine melanoma model. In order to stabilize this aquaporin inhibitor, allowing its in 
 
 
Timepoint (h) 
 48 72 
Compound 
IC50 ± SE (µM) R
2
 IC50 ± SE (µM) R
2
 
Auphen n.d. (-) 3.7 ± 1.2 0.990 
Auterpy n.d.  (-) n.d. (-) 
Cuphen 4.3 ± 1.1 0.988 3.0 ± 0.4 0.999 
Aubipy n.d. (-) n.d. (-) 
AubipyMe n.d. (-) 14.9 ± 1.1 0.995 
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vivo administration and targeting to tumors, this molecule was subsequently formulated in 
liposomes. These DDS are biodegradable, they are able to improve drug solubility, to protect 
the incorporated drug from premature degradation or metabolization while keeping its 
therapeutic activity. They also may change the PK and BD profiles of incorporated drug and 
consequently increasing the therapeutic efficacy. In addition, liposomes, depending on their 
lipid constituents, may reduce MPS capture and, taking the advantage of the impaired 
vasculature of tumors, may extravasate and accumulate in affected sites. 
 
 
Table 3.2. Cuphen physical properties. 
Chemical Structure 
 
Melting point No data available 
MW 314.66 
Partition coefficient: n-octanol/water No data available 
Dichloro(1,10-phenanthroline)copper(II); MSDS No. 362204: Sigma-Aldrich St. Louis, MO, USA, May 17, 
2013, http://www.sigmaaldrich.com/catalog/product/aldrich/362204 (accessed October 20, 2013). 
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3.2. Optimization of methodologies for Cuphen quantification 
As mentioned on chapter 2. Materials and Methods, Cuphen was quantified by UV-
spectrophotometry. To determine the wavelength of maximum absorption, serial dilutions were 
performed with EtOH and UV/Vis spectra were traced. In Figure 3.3 are shown the absorption 
spectra ranging from 200 to 800 nm and in a narrower range from 240 to 340 nm, respectively.  
 
 
Figure 3.3. UV spectra obtained for Cuphen solution at two different concentrations and 
wavelength ranges. Spectrum traced with a Cuphen solution of A| 20uM; B| 10uM. Absorbance 
maximum recorded at 272nm. 
After establishment of the appropriate wavelength for Cuphen, calibration curves were 
constructed using different concentrations ranging from 2 μM up to 20 μM. In Figure 3.4 a 
graphical representation of the calibration curves obtained for several independent experiments 
is shown. 
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Figure 3.4. Graphical representation of data sets of calibration curves for Cuphen. Data are 
represented as mean ± S.D. of several independent experiments (n=12). R
2 
- linear correlation coefficient: 
0.9983; Slope: 0.0331 ± 0.0017; Y-intercept (x=0): 0.0001 ± 0.0020. 
 
The obtained values evidence a high linearity and reproducibility in the selected range from 
different independent experiments.  
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3.3. Cuphen liposomes 
Liposomes were prepared by the dehydration-rehydration method followed by an extrusion step 
to reduce the mean size of the so formed vesicles. (Cruz, 1993; Gaspar, 1996, 2008) Once 
Cuphen presents hydrophilic character it was only added after formation of the lipidic film. Its 
incorporation occurs after formation of the lipidic film which is hydrated by the Cuphen 
solution (deionized water). Following the lyophilization (overnight) the rehydration step was 
performed with HEPES buffer in two steps, in order to increase Cuphen incorporation. (Lasch, 
2003) The extrusion of liposomal suspensions was performed in order to reduce and 
homogenize the mean size of the lipid suspension. Being a hydrophilic molecule the non 
incorporated material was removed by ultracentrifugation. 
 
 
3.3.1. Characterization of Cuphen liposomes 
Cuphen liposomes were prepared with different lipid compositions, i.e. phospholipids of 
different phase transition temperatures (Tc), with the aim to select the ones that were able to 
accommodate higher amounts of Cuphen per mol of lipid. Three neutral phospholipids - PC, 
DMPC and DPPC were used as major constituents of Cuphen nanoformulations that present 
increasing Tc of -6, +23, +41ºC, respectively.  
The inclusion of positively charged surfactant, SA, was also considered and the influence of its 
presence in Cuphen incorporation parameters was compared with neutral nanoformulations. In 
addition, as it is our intention to develop long circulating liposomes, another set of lipid 
compositions containing the polymer PEG was also prepared. 
The first series of nanoformulations was based on the natural phospholipid PC. In terms of 
charge this is a neutral phospholipid with a Tc of -6ºC. Considering its fluidity, Chol was 
included in the lipid composition to decrease the membrane permeability and consequently to 
enhance the stability of the incorporated Cuphen. 
In Table 3.3 the results obtained for different PC Cuphen formulations are summarized.  
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Table 3.3. Physicochemical characterization of Cuphen liposomes: PC-based vesicles. 
Formulation 
Lipid 
Composition 
(molar ratio) 
(Cuphen/Lip)i 
(nmol/μmol) 
(Cuphen/Lip)f 
(nmol/μmol) 
IE 
(%) 
Ø (µm) 
(P.I.) 
Zeta 
Pot. 
(mV) 
1 PC 34 ± 5 21 ± 7  54 ± 1 
0.15 
(<0.15) 
-9 ± 1 
2 
PC:Chol:PEG 
(1.85:1:0.15) 
39 ± 4 15 ± 3 47 ± 5 
0.16 
(<0.15) 
-4 ± 1 
3 
PC:Chol 
(2:1) 
39 ± 3 17 ± 2 44 ± 2 
0.20 
(<0.10) 
-9 ± 1 
4 
PC:SA 
(9.5:0.5) 
36 ± 1 22 ± 5 61 ± 1 
0.16 
(<0.15) 
-9 ± 1 
Initial lipid concentration [Lip]i – 20 µmol/mL; Initial Cuphen [Cuphen]i – 500 nmol/mL;  
PC transition temperature: -6ºC (Gunstone, 1986) 
I.E. (%) – Incorporation efficiency, [(Cuphen/Lip)f] / [(Cuphen/Lip)i] x 100;  
Ø – mean size of liposomes; P.I. – polydispersity index; Zeta Pot. – Zeta Potential. 
Results are expressed as mean ± S.D. 
 
All Cuphen liposomes presented mean sizes ranging from 0.15 to 0.20 µm with polydispersion 
index (P.I.) below 0.2 evidencing the high homogeneity of all nanoformulations.  
In terms of loading capacity, PC formulations without Chol (F1 and F4) were able to 
accommodate high amounts of Cuphen per µmol of lipid. Regarding to I.E. obtained values 
ranged from 54 to 61%. The inclusion of Chol in the lipid composition led to a decrease on 
incorporation parameters of F2 and F3. When included in the lipid composition of liposomes, 
Chol is inserted within bilayers competing with the accommodation of hydrophobic molecules. 
This finding is in accordance with literature (Blume, 1993; Constantino, 1993) suggesting that 
Cuphen, even presenting hydrophilic character, may also interact with the lipid bilayers, 
probably through phenantroline, leading to the I.E. values observed. 
Interestingly, all formulations in the absence of PEG presented similar zeta potential values (-9 
± 1 mV). Even for F4, the inclusion of SA was not able to reduce the negative charge of 
liposomes. In order to clarify these observations unloaded liposomes with the same lipid 
composition of F1 and F2 were prepared and the results obtained are shown in Table 3.4. 
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Table 3.4. Physicochemical properties of unloaded PC-based vesicles. 
Lipid composition 
(molar ratio) 
Ø (µm) 
(P.I.) 
Zeta Pot. (mV) 
PC 
0.14 
(0.1) 
-4 ± 1 
PC:Chol:PEG 
(1.85:1:0.15) 
0.14 
(0.1) 
-3 ± 1 
Ø – mean size of liposomes; P.I. – polydispersity index;  
Zeta Pot. – Zeta Potential. 
Results are expressed as mean ± S.D. 
 
According to these results, while for PC:Chol:PEG no differences on the zeta potential values 
were achieved (-3 ± 1 mV), the PC unloaded liposomes displayed less negative values (-4 ± 1 
mV) than those observed for F1 (-9 ± 1 mV). 
The different physicochemical properties observed for F1 and unloaded PC liposomes point out 
that Cuphen influences the superficial charge of the vesicles. 
In the second set of liposomal formulations tested the main phospholipid constituent was DMPC 
which presents a Tc of +23ºC. The influence of PEG and SA inclusion on Cuphen incorporation 
parameters was also evaluated and results are shown in Table 3.5. 
 
Table 3.5. Physicochemical characterization of Cuphen liposomes: DMPC-based vesicles. 
Formulation 
Lipid  
Composition 
(molar ratio) 
(Cuphen/Lip)i 
(nmol/μmol) 
(Cuphen/Lip)f 
(nmol/μmol) 
IE  
(%) 
Ø (µm) 
(P.I.) 
Zeta 
Pot. 
(mV) 
5 DMPC 33 ± 10 3 ± 2 8 ± 3 
0.19 
(<0.15) 
-1 ± 1 
6 
DMPC:Chol:PEG 
(1.85:1:0.15) 
32 ± 12 3 ± 1 9 ± 1 
0.19 
(<0.20) 
-3 ± 1 
7 
DMPC:SA 
(9.5:0.5) 
42 ± 20 3 ± 2 6 ± 2 
0.18 
(<0.15) 
+7 ± 1 
8 
DMPC:SA 
(9:1) 
27 ± 5 2 ± 1 6 ± 2 
0.16 
(<0.20) 
+18 ± 2 
Initial lipid concentration [Lip]i – 20 µmol/mL; Initial Cuphen [Cuphen]i – 500 nmol/mL;  
DMPC transition temperature: +23ºC (Gunstone, 1986) 
I.E. (%) – Incorporation efficiency, [(Cuphen/Lip)f] / [(Cuphen/Lip)i] x 100;  
Ø – mean size of liposomes; P.I. – polydispersity index; Zeta Pot. – Zeta Potential. 
Results are expressed as mean ± S.D. 
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All Cuphen liposomal formulations presented mean sizes ranging from 0.16 to 0.19 µm with 
polydispersion index (P.I.) below 0.2.  
Very low incorporation values, below 10%, were obtained for all tested formulations 
irrespective of charge or presence of PEG in the lipid composition. 
The zeta potential values observed for these nanoformulations were in accordance to the 
expected values (i.e. with the charge of constituents) where the i) neutral phospholipid confers a 
charge of about zero; ii) PEG confers a negative charge of approximately -3mV and iii) 
liposomes become positively charged in the presence of increasing molar ratio of SA. While for 
F4 negative values were observed when SA was included in the lipid composition, in this set of 
experiments F7 and F8 did not show the same feature. 
As performed for PC-based vesicles, unloaded liposomes were also prepared and results are 
shown in Table 3.6. 
 
Table 3.6. Physicochemical properties of unloaded DMPC-based vesicles. 
Lipid composition 
(molar ratio) 
Ø (µm) 
(P.I.) 
Zeta Pot. (mV) 
DMPC 
0.16 
(<0.15) 
-2 ± 1 
DMPC:Chol:PEG 
(1.85:1:0.15) 
0.15 
(<0.15) 
-3 ± 1 
DMPC:SA 
(9.5:0.5) 
0.16 
(<0.15) 
+6 ± 1 
DMPC:SA 
(9:1) 
0.15 
(<0.15) 
+18 ± 2 
Ø – mean size of liposomes; P.I. – polydispersity index;  
Zeta Pot. – Zeta Potential. 
Results are expressed as mean ± S.D. 
 
According to these results, no differences on the zeta potential values were observed for loaded 
and unloaded liposomes, particularly for DMPC:SA formulations. This fact might be due to the 
low incorporation parameters obtained for these nanoformulations and consequently the ability 
of Cuphen to interfere with the superficial charge is diminished.  
In the third set of liposomal formulations tested the main phospholipid constituent was DPPC 
which presents a Tc of +41ºC. The influence of PEG and SA inclusion on Cuphen incorporation 
parameters was evaluated and results are shown in Table 3.7. 
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Table 3.7. Physicochemical characterization of Cuphen liposomes: DPPC-based vesicles. 
Formulation 
Lipid 
Composition 
(molar ratio) 
(Cuphen/Lip)i 
(nmol/μmol) 
(Cuphen/Lip)f 
(nmol/μmol) 
IE 
(%) 
Ø (µm) 
(P.I.) 
Zeta 
Pot. 
(mV) 
9 DPPC 27 ± 5 2 ± 2 6 ± 3 
0.8 
(1.0) 
-1 ± 1 
10 
DPPC:Chol:PEG 
(1.85:1:0.15) 
35 ± 9 4 ± 2 10 ± 4 
0.2 
(<0.10) 
-3 ± 1 
11 
DPPC:SA 
(9:1) 
23 ± 4 2 ± 1 5 ± 3 
0.8 
(1.0) 
+16 ± 1 
Initial lipid concentration [Lip]i – 20 µmol/mL; Initial Cuphen [Cuphen]i – 500 nmol/mL;  
DPPC transition temperature: +41 ºC (Gunstone, 1986) 
I.E. (%) – Incorporation efficiency, [(Cuphen/Lip)f] / [(Cuphen/Lip)i] x 100;  
Ø – mean size of liposomes; P.I. – polydispersity index; Zeta Pot. – Zeta Potential. 
Results are expressed as mean ± SD. 
 
 
These DPPC-based vesicles displayed high mean sizes and P.I. values. During extrusion step, 
higher pressures were necessary to apply even being performed at a temperature of +50ºC, when 
compared to those used for PC and DMPC formulations. 
F9 and F11 were totally polydispersed according to the P.I. values that reached its maximum. 
Very low incorporation parameters, below 10%, were also obtained for DPPC–based vesicles, 
and zeta potential values observed were in accordance with the charge of lipid constituents.  
 
In conclusion and taking into account all the results presented in Tables 3.3-3.7, the 
incorporation of Cuphen in liposomes was dependent on the rigidity of the phospholipid and on 
the presence of Chol as shown in Figure 3.5. The presence of Chol and the higher the Tc of the 
phospholipid used led to a systematic decrease on Cuphen incorporation parameters. 
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Figure 3.5. Influence of the bilayer rigidity on Cuphen incorporation parameters: I.E. (%) (white 
columns) and [Cuphen/Lip]f (grey columns). Comparison between A| PC, DMPC and DPPC (F1, F5 
and F9); B| PC:Chol:PEG, DMPC:Chol:PEG and DPPC:Chol:PEG (F2, F6 and F10). Results are 
expressed as mean ± S.D. 
 
 
For pursuing in vitro tests the selected formulations were those prepared with PC (F1) and 
PC:Chol:PEG (F2) as they presented higher I.E. Although similar incorporation parameters 
were achieved for PC:SA they were not chosen for in vitro studies due to SA toxicity as 
reported in literature. (Takano, 2003; Epstein-Barash, 2010)  
 
 
3.4. In vitro cytotoxicity of Cuphen formulations 
The cytotoxic effect of Cuphen in the free and liposomal forms was evaluated against two 
different cell lines: the A431, already used in the first set of experiments, and the murine colon 
cancer cells, C26. The rational for choosing the C26 cell line was based on the fact related with 
i) the expression of AQP3 in colonic surface epithelium (Ma, 1999) and ii) as well as on the 
evidence of AQP3 overexpression in human colorectal tumors. (Moon, 2003)  
A| 
B| 
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Here, the cytotoxic potential of this AQP3 inhibitor in the free and liposomal forms was 
assessed by MTS method for at least two different incubation periods (24, 48, 72 or 96h). These 
in vitro methodologies were already optimized and published. (Calado, 2012)  
Negative control was constituted by the cell line under study in the presence of the culture 
medium. Unloaded liposomes also constituted another control group, using the same lipid 
concentrations as in loaded liposomes. 
 
 
3.4.1. Cytotoxicity of Cuphen against A431 cells  
For this human epidermoid carcinoma cell line, cells were incubated for 48 and 72h with 
Cuphen concentrations ranging from 0.625 μM up to 50 µM.  
 
Cuphen in free form 
After 48 and 72h of incubation with Cuphen in free form, significant cytotoxic effects were 
obtained as shown in Figure 3.6, by the dose-response curves traced. 
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Figure 3.6. Concentration-dependent inhibition of A431 cells proliferation after different times of 
incubation with Cuphen in the free form. (●) – 48h; (○) – 72h. Results are expressed as mean 
percentage (%) of control ± SD. 
 
Through the dose-response curves and at both incubation times, Cuphen was able to induce 
approximately 85% of cellular death, depending on the incubation period. In Table 3.8 the IC50 
values determined based on the previous traces are shown: 4.1 ± 0.4 and 2.7 ± 0.1 µM 48 and 
72h after incubation, respectively. The IC50 values are in accordance with the results obtained in 
the preliminary assay (p.34-35). 
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Table 3.8. Inhibition of the cellular proliferation of A431 cells by Cuphen 
in free form. Half-inhibitory concentrations. 
Timepoint (h) IC50 ± SE (µM) R
2
 
48 4.1 ± 0.4 0.970 
72 2.7 ± 0.1 0.991 
Results obtained from several independent experiments. R2 - Average linear 
correlation coefficients obtained by data curve fits. 
 
In order to compare the cytotoxic effect induced by this AQP3 inhibitor, cellular viability 48 
and 72h after incubation with 5 μM of Cuphen is discriminated in Figure 3.7. 
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Figure 3.7. Graphical representation of A431 cells proliferation inhibition induced by Cuphen (5 
μM) in free form 48 and 72h after incubation. Results are expressed as mean percentage (%) of control 
± SD. ***p<0.001. 
 
The inhibition of cellular proliferation by Cuphen in the free form was statistically significant in 
comparison with control (p<0.001). After 48h of incubation with 5 μM of Cuphen, cellular 
viability was already below 50%. For a longer incubation period (72h) the metallodrug was able 
to induce cell death in an extension of about 80%.  
 
 
Cuphen liposomes 
The cytotoxic potential of Cuphen liposomes was also evaluated against this human epidermoid 
carcinoma cell line and compared to results obtained for the inhibitor in the free form. For this 
set of experiments, incubation times were 48 and 72h and drug concentrations ranged from i) 
0.625 μM up to 50 μM for the free form and ii) 1.25 μM up to 50 μM for Cuphen liposomes. 
For unloaded liposomes, the lipid concentration range was the same as the one used in Cuphen 
liposomes. 
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Cuphen in the free form worked as a positive control, while unloaded liposomes and A431 cells 
constituted negative controls. The results obtained after 72h incubation period are shown in 
Figure 3.8. 
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Figure 3.8. Concentration-dependent inhibition of 431 cells proliferation after 72h of incubation.   
A| Unloaded liposomes; B| Cuphen formulations. (○) - Free Cuphen; (▲) – PC Cuphen liposomes; (x) – 
PC:Chol:PEG Cuphen liposomes. Results are expressed as mean percentage (%) of control ± SD.  
 
According to results displayed in Figure 3.8A, unloaded liposomes, using the same lipid 
concentration range as in Cuphen liposomes, did not exert any effect on the viability of A431 
cells after the longest incubation period. In Figure 3.8B, Cuphen liposomes were able to induce 
cell death at low micromolar range. However the IC50 was slightly higher than the one observed 
for Cuphen in the free form. Moreover, both liposomal formulations F1 and F2 showed similar 
cytotoxic effect against this epidermoid carcinoma cell line, as seen by the virtually overlapped 
curves. This fact is also easily seen through Figure 3.9 and Table 3.9, where the IC50 values are 
shown. The slight increase on IC50 values for Cuphen in liposomal form suggests that 
metallodrug remains partially incorporated in liposomes. The same observation was also 
reported in literature for other antitumor drugs after incorporation in liposomes. (Fens, 2008) 
 
Table 3.9. Inhibition of the cellular proliferation of A431 cells by Cuphen 
liposomes. Half-inhibitory concentrations. 
Formulation Timepoint (h) IC50 ± SE (µM) R
2
 
PC 
48 11.4 ± 1.1 0.905 
72 10.0 ± 0.8 0.934 
PC:Chol:PEG 
48 10.7 ± 1.0 0.925 
72 8.3 ± 0.8 0.940 
Results obtained from several independent experiments. R2 - Average linear correlation 
coefficients obtained by data curve fits. 
A| B| 
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Summarizing, Cuphen nanoformulations incorporated in PC and PC:Chol:PEG, presented IC50 
values of 10.0 ± 0.8 and 8.3 ± 0.8 μM, respectively after a 72h of incubation period. The linear 
correlation coefficients, R
2
, were superior to 0.900 for all the experiments.  
 
The cytotoxicity induced by Cuphen formulations, in free and liposomal forms was compared 
for a concentration of 15 μM following 48 and 72 h incubation period. Results are shown in 
Figure 3.9. 
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Figure 3.9. Graphical representation of A431 cells proliferation inhibition induced by Cuphen in 
free and liposomal forms at 15 μM. Different incubation times were tested A| 48 and B| 72h. Results are 
expressed as mean percentage (%) of control ± SD. *p<0.05; **p<0.01; ***p<0.001; n.s.: not statistically 
significant. 
 
Following a 48h incubation period, Cuphen in free and liposomal forms displayed cytotoxic 
effect against A431 cells showing a significant viability decrease of approximately 70 and 75% 
for Cuphen liposomes (p<0.001) in comparison with control. For this incubation period and for 
a Cuphen concentration of 15 µM statistically significant differences (p<0.01) were only 
observed between free Cuphen and Cuphen incorporated in PC liposomes according to Figure 
3.9A.  
Following the 72h of incubation period and according to results in Figure 3.9B no significant 
differences were observed between all Cuphen formulations.  
 
 
 
 
 
 
A| B| 
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3.4.2. Cytotoxicity of Cuphen against C26 cells  
Cuphen in free form 
The cytotoxic effect of Cuphen against the colon cancer cell line, the C26, was evaluated 
following incubation periods of 24, 48, 72 and 96h.  
The first approach in terms of in vitro studies was performed with this AQP3 inhibitor in free 
form in order to evaluate its potential cytotoxic activity against C26 cells. Incubation times of 
24, 48, 72 and 96h were tested with concentrations ranging from 0.625 μM up to 50 μM. 
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Figure 3.10. Concentration-dependent inhibition of C26 cells proliferation after different times of 
incubation with Cuphen in the free form. (□) – 24h; (●) – 48h; (○) – 72h; (♦) – 96h. Results are 
expressed as mean percentage (%) of control ± SD.  
According to the results obtained (Figure 3.10) progress curves are very similar 48, 72 and 96h 
after Cuphen incubation. These results point to a high response C26 cells to this AQP3 inhibitor 
according to IC50 values obtained and shown in Table 3.10. 
 
Table 3.10. Inhibition of the cellular proliferation of C26 cells 
by Cuphen in free form. Half-inhibitory concentrations.  
Timepoint (h) IC50 ± SE (µM) R
2
 
24 3.0 ± 0.4 0.981 
48 2.1 ± 0.2 0.986 
72 1.8 ± 0.1 0.998 
96 1.5 ± 0.1 0.997 
Results obtained from several independent experiments. R2 - Average 
linear correlation coefficients obtained by data curve fits. 
 
Cuphen proved to be quite effective by inhibiting the proliferation of this cancer cell line 
leading to IC50 values in low micromolar range.  
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Upon verification of the cytotoxic activity of Cuphen, in the free form, against this cancer cell 
line, liposomal formulations were also tested.  
Taking into account that Cuphen incorporated in liposomes is not immediately available for 
exerting its cytotoxic effect, the 24h of incubation period was not considered in the following 
experiments.  
 
Cuphen Liposomes 
Pursuing the idea of evaluating Cuphen liposomes efficiency against C26 murine cancer cell 
line, several independent experiments (six samples for each concentration under study) were 
performed. For this set of experiments, drug concentrations ranged from i) 0.625 μM up to 50 
μM for the free form and ii) 1.25 μM up to 50 μM for Cuphen liposomes. For unloaded 
liposomes, the lipid concentration range was the same as the one used in Cuphen liposomes. 
In order to estimate a possible improvement in the cytotoxic effect imposed by Cuphen 
liposomes the 96h incubation period was considered in addition to 48 and 72h timepoints. 
Cuphen in the free form worked as a positive control, while unloaded liposomes and C26 cells 
constituted negative controls. Figure 3.11 shows the representative dose-response curves traced 
for this set of experiments. 
 
 
-2 -1 0 1 2
0
20
40
60
80
100
log [Lip] ( M)
C
el
lu
la
r 
V
ia
b
il
it
y
 (
%
)
-2 -1 0 1 2
0
20
40
60
80
100
log [Cuphen] ( M)
C
el
lu
la
r 
V
ia
b
il
it
y
 (
%
)
 
Figure 3.11. Concentration-dependent inhibition of C26 cells proliferation after 72h of incubation. 
A| Unloaded liposomes; B| Cuphen formulations. (○) - Free Cuphen; (▲) – PC Cuphen liposomes; ( x ) – 
PC:Chol:PEG Cuphen liposomes. Results are expressed as mean percentage (%) of control ± SD. 
 
According to results displayed in Figure 3.11A, unloaded liposomes, using the same lipid 
concentration range as in Cuphen liposomes, did not exert any effect on the viability of C26 
cells after the 72h incubation period.  
A| B| 
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In Figure 3.11B, Cuphen liposomes were able to induce cell death at low micromolar 
concentrations range. Cytotoxic profiles are similar to those obtained for A431 cells (see Figure 
3.8). The half-inhibitory concentrations are show below, in Table 3.11. 
 
Table 3.11. Inhibition of the cellular proliferation of C26 cells by Cuphen liposomes. 
Half-inhibitory concentrations. 
Formulation Timepoint (h) IC50 ± SE (µM) R
2
 
PC 
48 7.3 ± 0.7 0.953 
72 5.8 ± 0.4 0.966 
96 5.4 ± 0.2  0.995 
PC:Chol:PEG 
48 7.3 ± 1.0 0.970 
72 4.4 ± 0.4 0.989 
96 4.2 ± 0.1  0.998 
Results obtained from several independent experiments. R2 - Average linear correlation coefficients 
obtained by data curve fits. 
 
From the results expressed in Table 3.11, IC50 values for both liposomal formulations at 48, 72 
and 96h incubation periods ranged from 4 to 7 µM. 
For this set of experiments and 72h after incubation, Cuphen formulations, prepared with PC 
and PC:Chol:PEG, presented IC50 values of 5.8 ± 0.4 and 4.4 ± 0.4 μM, respectively. For the 
free form and after the same incubation time the IC50 was of 1.9 ± 0.1 μM, which is in 
accordance to the result previously obtained. For all experiments, the linear correlation 
coefficients, R
2
, were higher than 0.950. 
 
The cytotoxicity induced by Cuphen formulations, in free and liposomal forms was compared 
for a concentration of 10 μM following 48, 72 and 96h incubation period. Results are shown in 
Figure 3.12.  
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Figure 3.12. Graphical representation of C26 cells proliferation inhibition induced by Cuphen in 
free and liposomal forms at 10 μM. Different incubation times were tested: A| 48h; B| 72h and C| 96h. 
Results are expressed as mean percentage (%) of control ± SD. ***p<0.001; n.s.: not statistically 
significant. 
 
As shown in Figure 3.12, after the 48h incubation period Cuphen liposomes were able to induce 
more than 50% of cellular death. Interestingly, Cuphen incorporated in PC and PC:Chol:PEG 
did not show statistically significant differences (p>0.05) in terms of cytotoxic effect (Figure 
3.12A). For the remaining incubation times studied it was expected to achieve similar results, 
with a progressive increase on cell death. However, for the 72h incubation period, PC Cuphen 
liposomes showed a significant improvement (p<0.001) in terms of cytotoxic activity when 
compared to PEG liposomes or even Cuphen in free form as seen in Figure 3.12B. This fact 
may be justified by the liposome constitution. Phosphatidylcholine, a more fluid lipid, yields a 
more fluid membrane that may enable Cuphen release in a shorter period of time. On the other 
hand, the results obtained for PEG liposomal formulation suggest that Cuphen still remains 
partially incorporated in the lipid system.  
Nevertheless, for the 96h incubation period (Figure 3.12C) Cuphen incorporated in PC and PEG 
liposomes displayed similar cytotoxic effect (p>0.05) inducing cell death at an extension of 
about 80%, as observed for the free molecule.  
 
 
 
A| 
B| C| 
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3.5. Storage stability of Cuphen liposomes 
In general, liposomal formulations are not produced to be stored in suspension for more than 
two weeks. The incorporated material may be released or chemical or physical instability of the 
phospholipids may occur. In addition, aqueous formulations tend to suffer hydrolytic 
degradation. (Kensil, 1981) The best storage condition for liposomes is the lyophilized form. 
(Frrkjaer, 1982) Using adequate lyophilization conditions it is possible to ensure the 
preservation of physicochemical properties of liposomal formulations.  
With the aim to evaluate the stability of Cuphen, in suspension, after incorporation in 
liposomes, its content was determined after a storage period of 10 days and compared with time 
zero, according to the following formula: [(Cuphen/Lip)t=10/(Cuphen/Lip)t=0] x 100. 
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Figure 3.13. Cuphen liposomes stability after storage at 4ºC for 10 days. Data from two independent 
experiments. Results are expressed as mean ± SD. 
 
 
As shown in Figure 3.13, PC and PC:Chol:PEG formulations are very stable as, particularly for 
PC, more than 90% of the incorporated Cuphen was still associated to liposomes 10 days after 
their preparation. 
 
Table 3.12. Physicochemical properties of Cuphen liposomes after 10 days in suspension. 
Formulation 
t=0 t=10 
Ø (µm) 
(P.I.) 
Zeta Pot. (mV) 
Ø (µm) 
(P.I.) 
Zeta Pot. (mV) 
PC 
0.17 
(<0.20) 
-9 ± 1 
0.18 
(<0.20) 
-9 ± 1 
PC:Chol:PEG 
0.16 
(<0.20) 
-4 ± 1 
0.18 
(<0.20) 
-5 ± 1 
Ø – mean size of liposomes; P.I. – polydispersity index;  
Zeta Pot. – Zeta Potential. 
Results are expressed as mean ± S.D. 
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In terms of mean size and zeta potential both formulations preserved their physicochemical 
properties as shown above in Table 3.12. These results reinforce the stability of the Cuphen 
liposomes in suspension after storage for 10 days. 
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Since 1992, when the first water channel was reported, AQPs have been subject of intensive 
studies. Although this family of proteins still lacks a full and comprehensive characterization, 
several important physiological functions have already been reported. In fact, the last decade 
was marked by the discovery of different pathologies somehow associated to AQPs. Recently 
AQP3, which is highly expressed in skin keratinocytes, was implicated in physiological 
processes like skin hydration and wound healing. This protein permeates both water and 
glycerol and, when overexpressed, greatly increases the intracellular concentration of glycerol. 
As consequence, cells possess high pools of an energetic substrate that is also essential for lipid 
synthesis. Thus, all the requirements for cellular proliferation are gathered. In addition, water 
transport by this channel also affords for cellular migration, another important event in 
tumorigenesis. Altogether, AQP3 appears to act as a key player during skin tumorigenesis and 
should be considered a new player in skin cancer biology. Consequently, the search for selective 
inhibitors of AQP3 is now even more relevant. Based on the well known inhibition of AQPs by 
HgCl2, and on the widely use of platinum in cancer therapy since the 80’s, many other 
compounds have emerged ever since. However, their toxicity is extremely elevated and, 
particularly for mercury-based compounds, their possible benefits do not compensate the risk. 
Recently, our group reported different metallodrugs as potent and selective inhibitors of human 
AQP3 that can be further explored on in vivo studies. Interestingly, all of the compounds are 
described as cytotoxic agents. 
The present work allowed us to conclude that Cuphen is a potent inhibitor of A431 and C26 
tumor cells proliferation, presenting IC50 values of 3.0 ± 0.4 μM and 1.8 ± 0.1 μM after 72h of 
drug incubation, respectively. As the best lead compound from the small library of AQP3 
inhibitors tested, this Cu(II) complex was selected to be incorporated in liposomes for future in 
vivo studies. After an optimization of the liposome preparation procedures, a systematic study 
using different lipid compositions was performed, aiming at the maximization of Cuphen 
incorporation parameters. Lipid mixtures containing PC and/or PEG allowed the achievement of 
incorporation efficiencies of approximately 50%. The association of Cuphen into liposomes was 
favored by fluid phospholipids, i.e. PC-based vesicles. Following the selection of the best 
formulations, Cuphen liposomes were tested in vitro against A431 and C26 cells. From these set 
of experiments we could conclude that the incorporation of Cuphen in liposomes was able to 
preserve the cytotoxic effect of this AQP3 inhibitor with IC50 values below 10 μM for both 
cancer cell lines, after 72h of incubation. Moreover, unloaded liposomes did not exert any effect 
on the viability of cancer cells, as intended for a drug carrier. 
 
In view of these promising in vitro results, the establishment of a murine melanoma model to 
evaluate the therapeutic effect of Cuphen formulations should be considered. 
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Future work 
The full understanding of the AQP3 role in skin tumorigenesis is still a distant reality. 
Notwithstanding, several efforts have been made in order to take advantage of the actual 
knowledge.  
The results presented and discussed in this thesis allowed us to look and move forward with a 
new perspective for cancer therapy having AQP3 as putative drug target. Based on this work, 
experiments aiming at different approaches can now be designed.  
The first approach will consist in the extension of the actual work to in vivo studies, through the 
establishment of an appropriate murine model allowing the evaluation of the therapeutic effect 
of Cuphen formulations. Additionally, the cellular membrane of a human melanoma cell line 
could be analyzed in order to explore possible useful characteristics for the optimization of drug 
targeting, in addition to the passive targeting that PEG implicates. 
Another approach would be the utilization of these metallodrugs as AQP3 inhibitors in a broad 
sense, testing for example, the same liposomal formulations with lower drug loading, aiming at 
targeting the channel inhibition without cell death. This perspective could not only elucidate 
about the AQP3 inhibition itself but also enlarge the actual state of the art on AQP3-dependent 
tumorigenesis. For this particular case, in silico and in vitro studies could be performed in order 
to infer about AQP3 inhibition by the intracellular entrance of the pore. Permeability assays 
with Cuphen liposomes could be considered as well. 
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